[conspire] COVID-19 and ME!

[Ruben Safir]

also
http://www.covid19-druginteractions.org/


Prescribing Resources

The Liverpool Drug Interaction Group (based at the University of
Liverpool, UK), in collaboration with the University Hospital of Basel
(Switzerland) and Radboud UMC (Netherlands), have produced various
materials in PDF format to aid the use of experimental agents in the
treatment of COVID-19.

Please check this site regularly for updates and additional information.
Overview of interactions with experimental COVID-19 therapies.

UPDATED – now includes hydroxychloroquine.

A summary of interactions with experimental COVID-19 therapies
(darunavir/cobicistat, lopinavir/ritonavir, remdesivir, favipiravir,
chloroquine, nitazoxanide, ribavirin) and over 400 comedications are
shown. Please use your browser’s “find” function to search for drug
names within the PDF. [The nature of the interactions for many of the
comedications are available in the “Further details of interactions…”
PDF below.]

Click here to view PDF.

Updated 16 March 2020
Further details of interactions with experimental COVID-19 therapies.

UPDATED – now includes hydroxychloroquine.

Details of the nature of drug interactions with experimental COVID-19
therapies (darunavir/cobicistat, lopinavir/ritonavir, remdesivir,
favipiravir, chloroquine, nitazoxanide, ribavirin) and many comedication
classes are given in the PDF below. Please use your browser’s “find”
function to search for drug names.

Click here to view PDF.

Updated 16 March 2020
Administration in cases of swallowing difficulties.

Advice for administering experimental COVID-19 therapies to patients who
cannot swallow is given in the pdf below.

Click here to view PDF.

Updated 14 March 2020
About us

The Liverpool Drug Interaction Group was established in 1999 by members
of the Department of Pharmacology at the University of Liverpool to
provide a freely available drug-drug interaction resource for drugs used
to treat HIV infection. Since then, our activity has expanded to
included drug interaction information for the treatment of hepatitis B
infection, hepatitis C infection, primary biliary cholangitis and
various cancers (in collaboration with Radboud UMC, Netherlands). These
interaction resources can be found at:

www.hiv-druginteractions.org

www.hep-druginteractions.org

www.cancer-druginteractions.org


On 3/17/20 12:46 AM, Ruben Safir wrote:
> https://link.springer.com/article/10.1007/s00134-020-05991-x
> 
> 
>     Letter
>     Published: 03 March 2020
> 
> Clinical predictors of mortality due to COVID-19 based on an analysis of
> data of 150 patients from Wuhan, China
> 
>     Qiurong Ruan, Kun Yang, Wenxia Wang, Lingyu Jiang & Jianxin Song
> 
> Intensive Care Medicine (2020)Cite this article
> 
>     51k Accesses
> 
>     1 Citations
> 
>     557 Altmetric
> 
>     Metrics details
> 
> Dear Editor,
> 
> The rapid emergence of COVID-19 in Wuhan city, Hubei Province, China,
> has resulted in thousands of deaths [1]. Many infected patients,
> however, presented mild flu-like symptoms and quickly recover [2]. To
> effectively prioritize resources for patients with the highest risk, we
> identified clinical predictors of mild and severe patient outcomes.
> 
> Using the database of Jin Yin-tan Hospital and Tongji Hospital, we
> conducted a retrospective multicenter study of 68 death cases (68/150,
> 45%) and 82 discharged cases (82/150, 55%) with laboratory-confirmed
> infection of SARS-CoV-2. Patients met the discharge criteria if they had
> no fever for at least 3 days, significantly improved respiratory
> function, and had negative SARS-CoV-2 laboratory test results twice in
> succession. Case data included demographics, clinical characteristics,
> laboratory results, treatment options and outcomes. For statistical
> analysis, we represented continuous measurements as means (SDs) or as
> medians (IQRs) which compared with Student’s t test or the
> Mann–Whitney–Wilcoxon test. Categorical variables were expressed as
> numbers (%) and compared by the χ2 test or Fisher’s exact test.
> 
> The distribution of the enrolled patients’ age is shown in Fig. 1a.
> There was a significant difference in age between the death group and
> the discharge group (p < 0.001) but no difference in the sex ratio
> (p = 0.43). A total of 63% (43/68) of patients in the death group and
> 41% (34/82) in the discharge group had underlying diseases (p = 0.0069).
> It should be noted that patients with cardiovascular diseases have a
> significantly increased risk of death when they are infected with
> SARS-CoV-2 (p < 0.001). A total of 16% (11/68) of the patients in the
> death group had secondary infections, and 1% (1/82) of the patients in
> the discharge group had secondary infections (p = 0.0018). Laboratory
> results showed that there were significant differences in white blood
> cell counts, absolute values of lymphocytes, platelets, albumin, total
> bilirubin, blood urea nitrogen, blood creatinine, myoglobin, cardiac
> troponin, C-reactive protein (CRP) and interleukin-6 (IL-6) between the
> two groups (Fig. 1b and Supplementary Table 1).
> 


-- 
So many immigrant groups have swept through our town
that Brooklyn, like Atlantis, reaches mythological
proportions in the mind of the world - RI Safir 1998
http://www.mrbrklyn.com
DRM is THEFT - We are the STAKEHOLDERS - RI Safir 2002

http://www.nylxs.com - Leadership Development in Free Software
http://www.brooklyn-living.com

Being so tracked is for FARM ANIMALS and extermination camps,
but incompatible with living as a free human being. -RI Safir 2013